Background
Amyloid-beta accumulation (Aβ) in the brain is a pathological hallmark of Alzheimer’s disease (AD) and can be measured in vivo using positron emission tomography (PET) [
1,
2]. One of the first amyloid PET tracers is Pittsburgh compound B ([
11C]PiB), which binds with high specificity to fibrillar Aβ deposits [
3,
4]. Both static and dynamic PET image acquisition protocols have been used, where the first is often preferred for routine and multi-centre studies due to its short duration and relatively simple processing. However, a static scan only provides a semi-quantitative measure of amyloid load, which can be affected by confounders [
5‐
8]. Therefore, performing dynamic acquisitions and full quantification using kinetic modelling may be required for assessing subtle changes in amyloid load, which is of particular importance in longitudinal studies where other physiological parameters may change, thereby introducing bias [
5]. In general, a disadvantage of such a protocol is the need for arterial sampling, which is logistically challenging, requires specially trained staff and dedicated equipment, and is particularly burdensome to the patient. A possible alternative to the use of arterial sampling is a reference tissue approach [
9]. Reference tissue approaches rely on the assumption that a region devoid of specific binding, but otherwise having similar tissue characteristics as the target region of interest, is available (= reference region), providing an indirect input function and circumventing the need for arterial sampling [
10,
11].
In case of imaging Aβ deposits in AD using [
11C]PiB, the cerebellar grey matter (GMCB) meets the assumptions of a reference region in nearly all patients, and it has been validated against the plasma input approach [
6,
12]. Only in rare familial forms and advanced stages of AD, this region might become compromised with Aβ plaques [
13,
14]. In addition, accurate segmentation of this region can be challenging and may be hampered by truncation of the field of view in the lower portion of the brain. In recent years, several reports have proposed alternative reference regions, either aiming to overcome these issues, or aiming to improve effect sizes when measuring Aβ changes over time [
15‐
17]. However, these alternative reference regions do not necessarily meet all requirements for a suitable reference tissue, such as having the same tissue characteristics as the target tissue or showing longitudinal stability and similar behaviour across diagnostic groups [
15,
16]. One such region often used for amyloid quantification is whole cerebellum [
16,
17]. Alternatively, reference tissues predominantly consisting of white matter, such as brainstem/pons or eroded subcortical white matter (centrum semiovale) have been proposed, in particular, for longitudinal amyloid quantification [
17,
18]. However, age-related changes have been reported in the non-specific tracer retention of white matter regions, possibly compromising their use for longitudinal amyloid quantification [
19].
To date, the impact of using alternative reference regions (RRs) on amyloid quantification has mainly been evaluated for semi-quantitative parameters [
15‐
17]. Most alternative RRs have not been validated against the gold standard, i.e. full quantification with metabolite corrected plasma input curves or full quantification using a validated reference region.
Therefore, the present work focussed on the widely used [11C]PiB amyloid PET tracer and evaluated the use of the validated cerebellar grey matter as well as four alternative reference regions: whole cerebellum, white matter brainstem/pons, whole brainstem and eroded subcortical white matter. The performance of these regions was evaluated for both semi- and fully quantitative analysis in a test–retest (TRT) and longitudinal setting in terms of precision with respect to TRT variability, accuracy compared with the gold standard, stability over time (in case of the standardized uptake value, SUV), power for group discrimination and detecting physiologically plausible, longitudinal accumulation processes.
Image acquisition
All subjects from the TRT study underwent a structural T1-weighted MR scan on a 1.5 T Siemens Sonata scanner (MPRAGE: matrix size 256 × 256 and 160 slices, voxel size 1.0 × 1.0 × 1.5 mm, echo time = 3.97 ms, repetition time = 2.700 ms, inversion time = 950 ms, flip angle 8°) and a test and same-day retest dynamic [
11C]PiB PET scan (except for one subject) on a Siemens ECAT EXACT HR + scanner [
21]. All participants first received a 10 min transmission scan for photon attenuation correction, followed by an intravenous [
11C]PiB injection and simultaneously starting a 90 min dynamic PET scan [
21]. Arterial blood was monitored continuously for the first 60 min using an online detection system and additional manual samples were drawn for calibration, to determine plasma to whole-blood ratios, and to measure plasma parent and metabolite fractions [
21]. For seven subjects, arterial blood data were not available or not of sufficient quality for at least one of the scans. In addition, for one subject, the second scan was not used due to severe motion between PET frames. Consequently, a total of
N = 6 test scans and
N = 5 retest scans with plasma input data were available.
With respect to the longitudinal study, subjects also underwent similar T1-weighted MR and dynamic [
11C]PiB PET scans at baseline, and follow-up (same scanners), 30.3 ± 5.4 (range 23–48) months later, but no arterial blood was sampled [
20].
Image processing
First, structural T1-weighted MR images were co-registered to their corresponding PET image. Next, PVE-lab software was used to segment grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF), as well as to delineate volumes of interest (VOIs) based on the Hammers atlas [
23,
24]. The following grey matter regions were used as target regions: medial and lateral anterior temporal lobe, posterior temporal lobe, superior, middle and inferior temporal gyrus, fusiform gyrus, parahippocampal and ambient gyrus, anterior and posterior cingulate gyrus, middle and orbitofrontal gyrus, gyrus rectus, inferior and superior frontal gyrus, pre- and post-central gyrus, superior parietal gyrus and the (infero)lateral remainder of the parietal lobe. In addition, a composite global cortical region was generated as the volume-weighted average across all target regions. The RRs included GMCB, whole cerebellum (WCB), white matter brainstem/pons (WMBS), whole brainstem (WBS) and the eroded subcortical white matter (WMES). The WMES was obtained by eroding the subject’s whole brain WM segmentation (using the
imerode function in MATLAB) and manually removing cerebellar and brainstem white matter. Corresponding time–activity curves (TACs) were obtained by superimposing VOIs on the dynamic PET scan.
Kinetic analysis
Only for scans where arterial plasma input data were available, the reversible two-tissue compartment model with four rate constants and additional blood volume fraction parameter (2T4k_V
b) was used to estimate the volume of distribution (
VT). Volume of distribution ratios (DVR
2T4k_Vb =
VT target /
VT reference) were calculated indirectly by using the validated GMCB as RR (here called: DVR
PI_GMCB) (= gold standard) [
6,
12].
For all scans, reference Logan (RLogan) was used to estimate DVR (DVR
RLOGAN). The implementation did not require fixing
k2′ (as per Eq. 7 from Logan et al. [
25]) and a linearization time (
t*) of 50 min p.i. was used [
6,
25]. In addition, the simplified reference tissue model (SRTM) was used to estimate binding potential (
BPND) with parameter fit boundaries optimized per RR (see Additional file
1: Supplementary Table 1), and
BPND + 1 (= DVR) was calculated for comparison [
10]. Finally, standardized uptake value ratios (SUVr) were calculated for two frequently used acquisition windows (40–60 and 60–90 min p.i., SUVr
40−60 and SUVr
60–90, respectively) [
6,
12]. For each reference tissue method, all RRs mentioned above were used.
Table 1
Subject demographics
Age | 64.3 ± 5.7 | 71.0 | 61.0 ± 3.0 |
Females (%) | 50% | 100% | 17% |
MMSE | 29.7 ± 0.5 | 28.0 | 20.7 ± 2.0 |
Age | 66.4 ± 7.3 | 67.4 ± 6.7 | 60.4 ± 5.4 |
Females (%) | 27% | 33% | 14% |
MMSE | 29.4 ± 0.5 | 27.2 ± 2.5 | 25.3 ± 2.3 |
Statistical analysis
Statistical analyses were performed in IBM SPSS Statistics for Windows Version 24.0 (IBM Corp. Armonk New York U.S.A.), GraphPad Prism for Windows Version 7.04 (La Jolla California, USA), and Origin Version 2019b (OriginLab Corporation, Northampton, Massachusetts, USA). For each reference region and method, regional outliers were defined based on the median absolute deviation (MAD3) criterion assuming a non-normal distribution [
26]. This resulted in a total of 36 values, across all subjects (from the 2T4k_V
b and SRTM models) being excluded from further analyses (see Additional file
1: supplementary materials for details). Differences in age and score on the Mini-Mental State Examination (MMSE) between diagnostic groups were assessed using nonparametric Kruskal–Wallis and post hoc Mann–Whitney
U tests, while differences in the proportion of males and females were tested with Chi-square tests. As the TRT cohort consisted of only one MCI subject, this subject was not used for comparison.
Test–retest cohort
First, using the composite global cortical value, relative test–retest variability was calculated per RR and method according to Eq.
1, where the estimate of global cortical amyloid load (DVR or SUVr) of the test scan is denoted as T and for the retest scan as R
$${\text{TrT}}\;{\text{variability}} \, (\%) = \frac{{\left| {T - R} \right|}}{{0.5 \cdot \user2{ }\left| {T + R} \right|}} \cdot 100$$
(1)
Second, based on results obtained from the test scans (
N = 6), agreement between regional quantification (for all RRs and reference tissue methods) and the gold standard (DVR
PI_GMCB) was assessed using Bland–Altman (BA) analysis [
27]. Next, linear regression analysis of the data points in the BA plots was used to assess whether (and to what extent) bias was dependent on underlying amyloid burden. Finally, correlations, slopes and intercepts between DVR
PI_GMCB and the corresponding parameter of interest derived from each of the RRs and methods were calculated using linear regression analysis.
Longitudinal cohort
A subset of subjects (N = 18) had information available on injected dose and patient weight, for which SUV TACs were calculated for all RRs. In addition, mean SUVs were calculated for all RRs and both acquisition windows (40–60 min and 60–90 min p.i.). The shape of the SUV TACs were assessed in the baseline scans, and the stability of the RRs over time was assessed using paired t tests with Bonferroni correction. Follow-up time was standardized to the average follow-up time across subjects (2.6 years) to account for between-subject differences.
Finally, as an exploratory analysis, the annual percentage change in the composite global cortical value was calculated per individual and for each of the RRs (according to Eq.
2)
$${\text{Annual}}\;{\text{percentage}}\;{\text{change}} = \frac{{{\text{FU}} - {\text{BL}}}}{{{\text{Years}}}} \cdot \frac{100}{{{\text{BL}}}}$$
(2)
With the parameter at follow-up scan as FU, at baseline scan as BL and Years stands for the number of years since baseline scan. These values were plotted against the baseline parameter and the relationship was assessed by fitting linear and quadratic models through the data. These models were chosen based on the previous literature and the known dose–response relationship of binding [
1,
28,
29], where the hypothesis is that amyloid burden measured with PET plateaus at later stages of the disease [
1]. Goodness of fit was assessed using the Akaike Information Criterion (AIC) [
30].
Discriminative ability reference regions
For the global cortical parameter of interest, derived using each of the methods and RRs, the ability to discriminate between visually Aβ positive and Aβ negative scans was assessed using Mann–Whitney
U tests with Bonferroni correction (using scans with stable longitudinal visual assessment:
N = 80). In addition, the Hodges–Lehmann estimate of the median difference was used as measure of the effect size [
31].
Discussion
In the present [11C]PiB study, the performance of five reference regions was evaluated. All reference regions yielded relatively small test–retest variability and showed good correlations with the gold standard DVRPI_GMCB. However, largest bias, as shown by the regression slopes and BA analyses, was observed for white matter-based RRs. In addition, the choice of reference region did not impact the ability to differentiate between Aβ positive and negative scans, but the largest effect sizes were obtained for GMCB and WCB. Furthermore, the longitudinal study showed that SUV changed over time for both WBS and WMBS RRs, but only when using the late acquisition window (60−90 min). Finally, the relationship between baseline amyloid and Aβ accumulation was best described by a quadratic model, as expected, for GMCB and WCB.
While the maximum TRT variability was 5.1% across methods, the WCB RR showed consistently lower variability (Table
2). This may be related to the fact that this region is less prone to segmentation errors than for example GMCB and has more counts compared with the brainstem as a result of its larger volume. In addition, WCB may also outperform WMES in terms of TRT variability because the latter showed bias that was more dependent on the underlying amyloid burden (Fig.
1 and Additional file
1: Supplementary Table 2b). Finally, all regional parameters of interest, derived using all methods and RRs, showed good correlations (
r ≥ 0.78) with regional DVR
PI_GMCB (Table
3).
Using GMCB and WCB as RR yielded, as expected, least bias as compared with the gold standard (as shown by the linear regression: Table
3 and BA analysis: Fig.
1 and Additional file
1: Supplementary Table 2a). RRs that primarily contained white matter showed substantial underestimation compared with values obtained by the plasma input model, except for WCB, were this underestimation was only observed for RLogan and SRTM (Table
3). This underestimation is likely a result of both the relatively high uptake in white compared with grey matter and the different kinetics in this tissue compared to other RRs as illustrated by Fig.
2. Furthermore, given that the two cerebellar as well as the two brainstem RR SUV TACs were very similar in shape, relatively small differences in performance with respect to precision and accuracy were expected. These findings also indicate that the effect of choice of tissue of the RR on quantification is smaller than the effect of using a different anatomical RR. Furthermore, for WMES RR, bias (as shown by the BA analysis) was most dependent on the underlying amyloid burden (Additional file
1: Supplementary Table 2b). Therefore, using WMES for normalization purposes could be problematic, in particular, for analysing regions or subjects spanning the AD continuum.
The longitudinal results showed significant decreases in WBS and WMBS SUV only for the late (60–90 min) acquisition window. However, a similar trend (although not significant) was present for the early (40–60 min) acquisition window. This finding might be related to the fact that SUV does not take flow changes into account [
20]. As such, using WBS or WMBS for normalization purposes, may result in an overestimation of the true Aβ load and this would be particularly problematic for longitudinal Aβ quantification [
19]. In fact, effects of these confounding factors may explain why some studies have reported increased power for detecting longitudinal changes or larger between group differences in rates of Aβ change, using white matter RRs [
32,
33]. Moreover, decreases in white matter SUV also may explain the lower pons and WMES SUVR values for groups of increasing disease severity (using GMCB as RR), as previously reported by Tryputsen and colleagues [
34], although the authors themselves provide a different explanation by suggesting it could be due to increasing GMCB Aβ load. Ideally, one would have used
VT for assessing the stability of RRs over time, but this was not possible as these subjects did not undergo arterial sampling.
Furthermore, results showed that although all RRs were able to discriminate between Aβ positive and Aβ negative scans, GMCB and WCB provided the highest effect sizes, while WMES provided the poorest results. Therefore, GMCB and WCB would be preferred for detecting more subtle between-group differences. These findings partially differ from some previous reports, likely due to differences in study population, study design or criteria used for defining the optimal RR. For example, some studies reported highest effect sizes for GMCB and pons or for WMES and pons when discriminating between diagnostic groups, which only partly agrees with the present results when discriminating between Aβ positive and Aβ negative scans [
35,
36]. Moreover, the high effect sizes reported for WM RRs could also be related to the effect of confounding factors, as discussed above. It should be noted, however, that these results belong to a group classification analysis, and hence they cannot be compared directly with findings from studies assessing the statistical power for detecting longitudinal changes in Aβ burden, that employ a within-subject design [
32,
34]. Finally, differences in the criteria used for identifying the optimal RR can have a significant impact on outcome. For example, while Schwarz and colleagues exclusively focused on longitudinal criteria to recommend a combination of voxels from supratentorial white matter and whole cerebellum as RR, the present study used a combination of criteria based on a comparison against the gold standard, test–retest variability and longitudinal performance [
33].
In the present study, an inverted u-shaped relationship between baseline amyloid load and Aβ accumulation was observed only for GMCB and WCB RRs. This pattern has been reported previously [
28,
37,
38], and is in line with the known sigmoidal dose response relationship of binding [
29]. It should be noted that this was only an exploratory analysis, and further studies are needed to explore this relationship and possible between group differences in Aβ accumulation (e.g. by diagnostic or Aβ status) in a larger dataset.
Taken together, the present results suggest that GMCB and WCB are suitable RRs with respect to analysing [
11C]PiB scans. Overall, accuracy as compared with the gold standard was higher using GMCB, while precision (as assessed by measurement variability and dependency of the bias on underlying Aβ burden) was more favourable using WCB. Therefore, in cross-sectional studies one might prefer GMCB, as it more closely adheres to the “truth”, while in longitudinal studies, where stability of results outweighs a small bias, WCB would be preferred. Finally, it is important to note that the results of the present study relate to [
11C]PiB and are not necessarily translatable to other tracers. As shown previously by Villemagne and colleagues for SUVr, the most stable RR may differ per tracer [
39], and this finding was supported by studies using both [
18F]florbetaben and [
18F]florbetapir [
16,
40]. These between-tracer discrepancies may be the result of differences in non-specific binding in the reference region (as compared with the F-18 labelled tracers) or violations of the reference tissue approach. Hence, they emphasize the importance of a per tracer evaluation of suitable RRs.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.